表紙
市場調査レポート

PharmaPoint:2型糖尿病 - ブラジルにおける医薬品の予測と市場分析

PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 289936
出版日 ページ情報 英文 211 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
PharmaPoint:2型糖尿病 - ブラジルにおける医薬品の予測と市場分析 PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022
出版日: 2013年07月31日 ページ情報: 英文 211 Pages
概要

当レポートでは、ブラジルにおける2型糖尿病治療薬市場について調査分析し、疾病の概要とガイドライン、競合情勢、主要薬剤の詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
    • 予後
    • 生活の質(QOL)
  • 症状

第4章 疾病の管理

  • 治療の概要
    • 診断と紹介
    • 治療ガイドライン
  • ブラジル
    • 診断
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル - 主要ブランド
    • メトホルミン
    • スルホニル尿素、その他のインスリン分泌促進薬
    • αグルコシダーゼ阻害薬(AGI)
    • チアゾリジンジオン(TZD)
    • GLP-1受容体作動薬
    • DPP-4阻害薬
    • SGLT-2阻害薬
    • インスリン製剤

第6章 機会とアンメットニーズ

  • 概要
  • アンメットニーズ
  • アンメットニーズのギャップ分析
  • 持続可能な効果を有する経口療法
  • 減量を伴う経口療法
  • 有酸素運動による代謝治療
  • 新興市場における2型糖尿病治療薬の推進

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤
    • Albiglutide
    • Dulaglutide (LY2189265)
    • MK-3102
    • Fasiglifam (TAK-875)
    • LY2409021
    • LY2605541 (insulin peglispro)

第8章 市場の見通し

  • ブラジル
    • 予測
    • 主なイベント
    • 促進要因・障壁

第9章 付録

図表

目次
Product Code: GDHC142CFR

GlobalData has released its new Country report, "PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022". The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth. We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the novel class of SGLT-2 inhibitors will occur; however, DPP-4 inhibitors and GLP-1 receptor agonists will continue dominating the noninsulin type 2 diabetes space. GLP-1 receptor agonists will experience the fastest growth of all classes (CAGR of 17%), due to their weight-loss effects and their novel once-weekly administration, which is preferable to the standard once- or twice-daily therapies.

The Brazilian type 2 diabetes patient pool is expected to grow significantly due to the increasingly elderly population, insurance coverage and increasing awareness of and emphasis on early diagnosis. Physicians, hospitals and other healthcare providers may be reluctant to purchase the branded drugs if costs are not reimbursed by third-party payers.

Scope

  • Overview of type 2 diabetes including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Brazil from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Brazil type 2 diabetes market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Brazil

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Diagnosis and Referrals
    • 4.1.2. Treatment Guidelines
  • 4.2. Brazil
    • 4.2.1. Diagnosis
    • 4.2.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Metformin
    • 5.3.2. Sulfonylureas (SUs) and Other Insulin Secretagogues
    • 5.3.3. α-glucosidase Inhibitors (AGIs)
    • 5.3.4. Thiazolidinediones (TZDs)
    • 5.3.5. GLP-1 Receptor Agonists
    • 5.3.6. DPP-4 Inhibitors
    • 5.3.7. SGLT-2 Inhibitors
    • 5.3.8. Insulin Formulations

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Drugs Providing Sustained Glycemic Control
    • 6.2.2. Drugs with Non-Glycemic Benefits
    • 6.2.3. Increased Patient Compliance
    • 6.2.4. Drugs with Improved Side-Effect Profiles
    • 6.2.5. Earlier Diagnosis
  • 6.3. Unmet Needs Gap Analysis
  • 6.4. Oral Therapy with Sustainable Efficacy
  • 6.5. Oral Therapy Offering Weight Loss
  • 6.6. Cardio-metabolic Therapy
  • 6.7. Promotion of Type 2 Diabetes Drugs in Emerging Markets

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Albiglutide
    • 7.2.2. Dulaglutide (LY2189265)
    • 7.2.3. MK-3102
    • 7.2.4. Fasiglifam (TAK-875)
    • 7.2.5. LY2409021
    • 7.2.6. LY2605541 (insulin peglispro)

8. Market Outlook

  • 8.1. Brazil
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Type 2 Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Analyst II - CVMD
    • 9.6.2. Therapy Director - CVMD and Infectious Disease
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Type 2 Diabetes
  • Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes
  • Table 3: Treatment Guidelines for Type 2 Diabetes
  • Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012
  • Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012
  • Table 6: Product Profile - Metformin
  • Table 7: Metformin SWOT Analysis, 2012
  • Table 8: First-Generation Sulfonylureas
  • Table 9: Second-Generation Sulfonylureas
  • Table 10: Product Profile - Sulfonylureas
  • Table 11: Sulfonylureas SWOT Analysis, 2012
  • Table 12: Product Profile - Acarbose
  • Table 13: AGIs SWOT Analysis, 2012
  • Table 14: Product Profile - Actos
  • Table 15: Actos SWOT Analysis, 2012
  • Table 16: GLP-1 Receptor Agonists
  • Table 17: Product Profile - Byetta
  • Table 18: Byetta SWOT Analysis, 2012
  • Table 19: Product Profile - Victoza
  • Table 20: Victoza SWOT Analysis, 2012
  • Table 21: Product Profile - Bydureon
  • Table 22: Bydureon SWOT Analysis, 2012
  • Table 23: Product Profile - Lyxumia
  • Table 24: Lyxumia SWOT Analysis, 2012
  • Table 25: Marketed DPP-4 Inhibitors
  • Table 26: Marketed DPP-4 Inhibitors in Combination with Other OADs
  • Table 27: Product Profile - Januvia
  • Table 28: Januvia SWOT Analysis, 2012
  • Table 29: Product Profile - Onglyza
  • Table 30: Onglyza SWOT Analysis, 2012
  • Table 31: Product Profile - Tradjenta
  • Table 32: Tradjenta SWOT Analysis, 2012
  • Table 33: Product Profile - Galvus
  • Table 34: Galvus SWOT Analysis, 2012
  • Table 35: Global Sales Forecasts ($m) for Galvus and Eucreas, 2012-2022
  • Table 36: Product Profile - Forxiga
  • Table 37: Forxiga SWOT Analysis, 2012
  • Table 38: Product Profile - Invokana
  • Table 39: Invokana SWOT Analysis, 2012
  • Table 40: Insulins - Overview and Comparison
  • Table 41: Insulin Formulations
  • Table 42: Product Profile - Humalog
  • Table 43: Humalog SWOT Analysis, 2012
  • Table 44: Product Profile - Lantus
  • Table 45: Lantus SWOT Analysis, 2012
  • Table 46: Product Profile - Levemir
  • Table 47: Levemir SWOT Analysis, 2012
  • Table 48: Product Profile - Novolog
  • Table 49: Novolog SWOT Analysis, 2012
  • Table 50: Product Profile - Apidra
  • Table 51: Apidra SWOT Analysis, 2012
  • Table 52: Product Profile - Tresiba
  • Table 53: Tresiba SWOT Analysis, 2012
  • Table 54: Overall Unmet Needs - Current Level of Attainment
  • Table 55: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 56: Type 2 Diabetes - Phase Pipeline, 2012
  • Table 57: Comparison of Therapeutic Classes in Development for Type 2 Diabetes, 2012
  • Table 58: Product Profile - Albiglutide
  • Table 59: Albiglutide SWOT Analysis, 2013
  • Table 60: Product Profile - Dulaglutide
  • Table 61: Dulaglutide SWOT Analysis, 2012
  • Table 62: Product Profile - MK-3102
  • Table 63: MK-3102 SWOT Analysis, 2013
  • Table 64: Product Profile - Fasiglifam
  • Table 65: Fasiglifam SWOT Analysis, 2013
  • Table 66: Product Profile - LY2409021
  • Table 67: LY2409021 SWOT Analysis, 2013
  • Table 68: Product Profile - LY2605541
  • Table 69: LY2605541 SWOT Analysis, 2013
  • Table 70: Brazil Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022
  • Table 71: Key Events Impacting Sales for Type 2 Diabetes in Brazil, 2012-2022
  • Table 72: Type 2 Diabetes Market - Drivers and Barriers in Brazil, 2012
  • Table 73: Key Launch Dates
  • Table 74: Key Patent Expiries
  • Table 75: Number of High-Prescribing Physicians Surveyed

List of Figures

  • Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Type 2 Diabetes, 2012-2022
  • Figure 3: Sales for Type 2 Diabetes in Brazil by Drug Class, 2012-2022
Back to Top